Effective prophylaxis with rFVIIa in young haemophiliacs with inhibitors using a schedule similar to FVIII prophylaxis in non-inhibitor patients
María Fernanda López-Fernández, Carmen Altisent, Víctor Jiménez-Yuste, Faustino García-Candel, Carmen Sedano, Ana Cid, Eva Mingot, Ramiro Núñez, María José Paloma, Inmaculada Soto, Manuel Prieto
Congenital Coagulophaties Unit, Hospital Universitario La Fe, Valencia, Spain.
Haematology, Complejo Hospitalario Universitario A Coru?a, A Coru?a, Spain.
Haematology, Complejo Hospitalario Universitario Marques de Valdecilla, Santander, Spain.
Haematology, Hospital General de Asturias, Oviedo, Spain.
Haematology, Hospital General Yagüe, Burgos, Spain.
Haematology, Hospital Universitario Carlos Haya, Málaga, Spain.
Haematology, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Haematology, Hospital Virgen del Camino, Pamplona, Spain.
Haemophilia Unit, Hospital Universitario Vall d’Hebron, Barcelona, Spain.
Haemophilia Unit, Hospital Universitario Virgen de la Arreixaca, Murcia, Spain.
Haemophilia Unit, Hospital Universitario, Madrid, Spain.
DOI: 10.4236/health.2013.57155   PDF    HTML     3,726 Downloads   5,429 Views   Citations


Objective: To assess the role of early prophylaxis with recombinant activated factor VII (rFVIIa) in young haemophiliacs with inhibitors and to determine whether it can reduce bleeding episodes and prevent joint damage. Patients and Methods: Ten severe haemophiliacs, less of three years old, with up to four joint bleeds and inhibitors to FVIII who started early prophylaxis with rFVIIa, were included. A number of haemorrhages/year/patient and haemarthroses/ year/patient were compared before the start of prophylaxis, which include both the time before (initial period) and after inhibitor diagnosis (inhibitor period), with those during prophylaxis (prophylaxis period). Results: The mean time of inhibitor diagnosis was 15.6 months (range: 2.3-34.1). The mean time between inhibitor diagnosis and the start of prophylaxis was 7.1 months (range: 0-23.2), shorter than the time of rFVIIa prophylaxis (mean: 10.3 months; range: 4.1-32.0). Bleeding episodes for the three time periods were 45, 36 and 17, respectively, or 0.29 and 0.51 haemorrhages/year/patient in the two periods prior to prophylaxis compared to 0.17 during prophylaxis. Total haemarthroses for the three-time periods were 7, 5 and 5, respectively. The haemarthroses/year/patient in the pre-prophylaxis period were 0.032 and 0.070, compared to0.049 inthe prophylaxis period. rFVIIa schedules were either 90 μg/kg three times weekly or 90 μg/kg daily. Conclusions: Early prophylaxis with rFVIIa may be efficacious in young haemophiliacs with inhibitors, reducing joint bleeds. After the risky period of inhibitor presence, they are able to continue rFVIII prophylaxis with success assured to prevent arthropathy.

Share and Cite:

López-Fernández, M. , Altisent, C. , Jiménez-Yuste, V. , García-Candel, F. , Sedano, C. , Cid, A. , Mingot, E. , Núñez, R. , Paloma, M. , Soto, I. and Prieto, M. (2013) Effective prophylaxis with rFVIIa in young haemophiliacs with inhibitors using a schedule similar to FVIII prophylaxis in non-inhibitor patients. Health, 5, 1151-1157. doi: 10.4236/health.2013.57155.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Manco-Johnson, M.J., Abshire, T.C., Shapiro, M.D., Riske, B., Hacker, M.R., Kilcoyne, R., et al. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. The New England Journal of Medicine, 357, 535-544. doi:10.1056/NEJMoa067659
[2] Dobón, M., Lucía, J.F., Aguilar, C., Mayayo, E., Roca, M., Solano, V., et al. (2003) Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia, 9, 76-85. doi:10.1046/j.1365-2516.2003.00702.x
[3] Fischer, K., Van Hout, V.A., Van der Brom, J.G., Grobbee, D.E. and van den Berg, H.M. (2002) Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiologica, 43, 528-532. doi:10.1034/j.1600-0455.2002.430514.x
[4] Gringeri, A., Mantovani, L.G., Scalone, L. and Mannucci, P.M. (2003) Cost of care and quality of life for patients with hemophilia complicated by inhibitors: The COCIs study group. Blood, 102, 2358-2363. doi:10.1182/blood-2003-03-0941
[5] Abshire, T. and Kenet, G. (2004) Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. Journal of Thrombosis and Haemostasis, 2, 899-909. doi:10.1111/j.1538-7836.2004.00759.x
[6] Obergfell, A., Auven, M.K. and Mathew, P. (2008) Recombinant activated factor VII for hemophilia patients with inhibitors undergoing orthopedic surgery: A review of literature. Haemophilia, 14, 233-241. doi:10.1111/j.1365-2516.2007.01617.x
[7] Saxon, B.R., Shanks, D., Jory, C.B. and Williams, V. (2001) Effective prophylaxis with daily recombinant factor VIIa (rFVIIa.Novoseven) in child with high titre inhibitors and target joint. Journal of Thrombosis and Haemostasis, 86, 1126-1127.
[8] Young, G., McDaniel, M. and Nugent, D.J. (2005) Prophylactic recombinant factor VIIa in haemophiliac patients with inhibitors. Haemophilia, 11, 203-207. doi:10.1111/j.1365-2516.2005.01096.x
[9] Morfini, M., Ausrswald, G., Kobelt, R.A., Rivolta, G.F., Rodriguez-Martorell, J., Scaraggi, F.A., et al. (2007) Prophylactic treatment of haemophilia patients with inhibittors: Clinical experience with recombinant factor VIIa in European Haemophilia Centers. Haemophilia, 13, 502-507. doi:10.1111/j.1365-2516.2007.01455.x
[10] Blatny, J. and Smith, O. (2008) Prophylaxis with recombinant factor VIIa during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia, 11, 1140-1142. doi:10.1111/j.1365-2516.2008.01767.x
[11] Jimenez-Yuste, V., Quintana, M., Alvarez, M.T., Martín-Salces, M. and Hernández-Navarro, F. (2008) Primary prophylaxis with rVIIa in a patient with severe haemophilia and inhibitor. Blood Coagulation & Fibrinolysis, 19, 719-720. doi:10.1097/MBC.0b013e328309907a
[12] Konkle, B.A., Ebbesen, L.S., Erhardtsen, E., Bianco, R.P., Lissitchkov, T., Rusen, L., et al. (2007) Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 5, 1904-1913. doi:10.1111/j.1538-7836.2007.02663.x
[13] Rodriguez-Merchan, E.C., Hedner, U., Heijnen, L., Jinez-Yuste, V., Lee, C.A., Morfini, M., et al. (2008) Prention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors? Haemophilia, 14, 68-81. doi:10.1111/j.1365-2516.2008.01892.x
[14] Hilgartner, M.W., Markipernna, A. and DiMichele, D.M. (2003) Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia, 9, 261-268. doi:10.1046/j.1365-2516.2003.00771.x
[15] López Fernández, M.F., Andón Saavedra, C., Amor Otero, M.A. and Batlle, J. (2007) “Primary” prophylactic treatment with recombinant activated factor VII (rFVIIa) during immume tolerance in a haemophilic child. The 21st Congress of ISTH, Geneva, 6-11 July 2007, Abstract PM-161.
[16] Jiménez-Yuste, V., Alvarez, M.T., Martín-Salces, M., Quin-tana, M., Rodríguez-Merchan, C., López-Cabarcos, C., et al. (2009) Prophylaxis in 10 patients with severe haemophilia A and inhibitor: Different approaches for different clinical situations. Haemophilia, 15, 203-209. doi:10.1111/j.1365-2516.2008.01915.x
[17] Teitel, J., Berntorp, E., Dolan, G., Fischer, K., Gringeri, A., Kessler, C., Lambert, T., et al. (2011) A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients. Haemophilia, 17, 516-521. doi:10.1111/j.1365-2516.2010.02440.x
[18] Young, G., Auerswald, G., Jimenez-Yuste, V., Konkle, B.A., Lambert, T., Morfini, M., Sabtagostino, E., and Blanchette, V. (2011) When should prophylaxis therapy in inhibitor patients be considered? Haemophilia, 17, e849-e857.
[19] Coppola, A., Di Minno, M.N.D. and Santagostino, E. (2010) Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibittors: Towards evidence-based approaches. British Journal of Haematology, 150, 515-528. doi:10.1111/j.1365-2141.2010.08263.x
[20] Santagostino, E., Morfini, M., Auerswald, K.H., Benson, G.M., Alek, S.Z.S., Lambert, T., et al. (2009) Paediatric haemophilia with inhibitors: Existing management options, treatment gaps and unmet needs. Haemophilia, 15, 983-989. doi:10.1111/j.1365-2516.2009.01999.x
[21] Donatel-Claeyssens, S. (2006) European pediatric network for haemophilia management. Current coordinated activities of the PEDNET (European Pediatric Network for Haemophilia Management). Haemophilia, 12, 124-127. doi:10.1111/j.1365-2516.2006.01202.x
[22] Berntorp, E. and Michelis, J.J. (2003) A healthy hemophilic patient without arthropathy: From concept to clinical reality. Seminars Thromb Hemostas, 29, 5-10. doi:10.1055/s-2003-37934
[23] Fischer, K., Van Hout, V.A., Van der Brom, J.G., Grobbee, D.E. and van den Berg, H.M. (2002) Association between joint bleeds and Pettersson scores in severe haemophilia. Acta Radiologica, 43, 528-532. doi:10.1034/j.1600-0455.2002.430514.x
[24] Hay, C.R.M., Goldberg, I., Foulkes, M. and Dimechele, D.M. (2010) International prospective randomized immune tolerance study: Interim analysis of therapeutic efficacy and safety. Haemophilia, 16, 5.
[25] López-Vílchez, I., Tusell, J., Hedner, U., Altisent, C., Escolar, G. and Galán, A.M. (2009) Traffic of rFVIIa through endothelial cell and redistribution into subendothelium: Implications for a prolonged haemostatic effect. Journal of Coagulation Disorders, 1, 1-6.
[26] Mandal, S.K., Pendurthi, U.R. and Rao, M. (2007) Tissue factor trafficking in fibroblasts: Involvement of protease-activated receptor-mediated cell signalling. Blood, 110, 161-170. doi:10.1182/blood-2006-10-050476
[27] Hedner, U. (2006) Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. Journal of Thrombosis and Haemostasis, 4, 2498-2500. doi:10.1111/j.1538-7836.2006.02166.x

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.